We have used the same dose in previous experiments including an assessment of the effects of dabrafenib (a BRAF inhibitor) on AngII-induced hypertension, in which we also demonstrated how the disease progresses towards heart failure over 28 d [57]. This evidence concerns the gene BRAF and Hypertension.